Skip to main content

Arthritis: Medical Treatments

Question for Department of Health and Social Care

UIN 115007, tabled on 12 November 2020

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 3 November 2020 to Question 103607 on Arthritis: Medical Treatments, whether his Department plans to make an assessment of the effect of the covid-19 outbreak on the treatment of arthritis.

This answer is the replacement for a previous holding answer.

Answered on

8 January 2021

While no specific assessment was made, NHS England and NHS Improvement rapidly convened a COVID-19 musculoskeletal (MSK) stakeholder group at the beginning of the pandemic, led by the MSK National Clinical Director, and involving a range of professional, charity and patient groups including the Arthritis and Musculoskeletal Alliance (ARMA) and Versus Arthritis. This led to the development of a self-management resource for patients, including those with arthritis, in managing their condition at home during the COVID-19 pandemic.

NHS England and NHS Improvement continue to collaborate with ARMA and Versus Arthritis, as well as other key stakeholders, to provide guidance, support and communication to the National Health Service for people with arthritis, both in the current context of the pandemic and in the restoration of services. This collaboration recently led to a rapid assessment of the challenges experienced by patients with arthritis during the pandemic.

Answered by

Department of Health and Social Care
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.